Katerzia is owned by Azurity.
Katerzia contains Amlodipine Benzoate.
Katerzia has a total of 8 drug patents out of which 0 drug patents have expired.
Katerzia was authorised for market use on 08 July, 2019.
Katerzia is available in suspension;oral dosage forms.
Katerzia can be used as angina pectoris; angina, a method of treating coronary artery disease; a method of treating hypertension, treatment of hypertension; method of treating hypertension.
The generics of Katerzia are possible to be released after 11 April, 2039.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11471409 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
US11484498 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(16 years from now) |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: A method of treating coronary artery disease; A method of treating hypertension; Angina pectoris; Angina; Treatment of hypertension; Method of treating hypertension
Dosage: SUSPENSION;ORAL
14
United States
3
European Union
2
Canada
1
Japan
1
Spain
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic